Skip to content

Discerning Data

  • About Us
  • Additional Resources
  • Contact Us

DISCERNING DATA

A Faegre Drinker Blog Covering the Latest in Privacy, Cybersecurity and Data Strategy

  • Privacy
  • Cybersecurity
  • Data Strategy
  • Disruptionware

New FDA Guidance on Waiver of Informed Consent for Minimal Risk Investigations

Share

The FDA recently issued new guidance that allows institutional review boards (IRBs) to waive or alter the FDA’s informed consent requirements for certain minimal risk clinical investigations without objection from the FDA.

The statutory basis for the guidance comes from amendments made by the 21st Century Cures Act from late in 2016 (P.L 144-255). This guidance, which took effect on July 25, 2017, is the first step for the FDA on this issue.  The FDA intends to implement subsequent regulations to permit IRB waiver or alterations of informed consent requirements for minimal risk clinical investigations.

The types of “minimal risk” clinical investigations for which the informed consent requirements may be waived or altered by the IRB, are those for which the IRB may determine “that the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests.”

To waive informed consent for such minimal risk clinical studies, the IRB must determine that:

  • the clinical investigation involves no more than minimal risk to the subjects
  • the waiver or alteration will not adversely affect the rights and welfare of the subjects
  • the clinical investigations could not practicably be carried out without the waiver or alteration
  • whenever appropriate, the subjects will be provided with additional pertinent information after participation.

Thus, for example, if a sponsor desires to perform a new clinical investigation to support a drug application on existing data or biospecimens from a prior clinical investigation, but did not previously obtain appropriate informed consent from research subjects for the proposed clinical investigation, there is now a pathway to conduct the clinical investigation through an IRB waiver.

The Federal Policy for the Protection of Human Subjects (FPPHS) already permits IRB waiver or alteration for research involving minimal risk to research subjects.  The guidance now permits such IRB waivers or alterations for FDA regulated clinical investigations in the same manner as it does for studies subject to FPPHS.  If the research data at issue is maintained by an entity subject to HIPAA, a request for an IRB to waive HIPAA’s authorization requirements could also be made.

The material contained in this communication is informational, general in nature and does not constitute legal advice. The material contained in this communication should not be relied upon or used without consulting a lawyer to consider your specific circumstances. This communication was published on the date specified and may not include any changes in the topics, laws, rules or regulations covered. Receipt of this communication does not establish an attorney-client relationship. In some jurisdictions, this communication may be considered attorney advertising.

Receive Email Alerts to New Articles

SUBSCRIBE

August 14, 2017
Written by: Discerning Data Editorial Board
Category: Health Care, Privacy
Tags: FDA, HHS, HIPAA

Post navigation

Previous Previous post: Beyond FERPA: Safeguarding Student Data Is Key Obligation for Postsecondary Educational Institutions
Next Next post: Fact Sheet: NYDFS Cyber Regulations

Search the Blog

Sign Up for Email Alerts

PODCASTS

Faegre Drinker on Law and Technology

©2023 Faegre Drinker Biddle & Reath LLP. All Rights Reserved. Lawyer Advertising.

  • About Us
  • Additional Resources
  • Contact Us
We use cookies to improve your experience with our website. By browsing our site, you are agreeing to the use of cookies. For more information about how we use cookies, please review our privacy policy and cookie policy. OK
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT